Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.
This report offers an overview of the market trends, drivers, and barriers with respect to the China LATAM Adalimumab market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China LATAM Adalimumab market. Detailed analysis of key players, along with key growth strategies adopted by LATAM Adalimumab industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Novartis AG
Boehringer Ingelheim GmbH
By Type:
Oral Type
Injection Type
By End-User:
Rheumatoid Arthritis
Psoriasis
Crohn’s Disease
Ulcerative Colitis
Others
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of LATAM Adalimumab Market
-
1.3 Market Segment by Type
-
1.3.1 China LATAM Adalimumab Market Size and Growth Rate of Oral Type from 2016 to 2027
-
1.3.2 China LATAM Adalimumab Market Size and Growth Rate of Injection Type from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China LATAM Adalimumab Market Size and Growth Rate of Rheumatoid Arthritis from 2016 to 2027
-
1.4.2 China LATAM Adalimumab Market Size and Growth Rate of Psoriasis from 2016 to 2027
-
1.4.3 China LATAM Adalimumab Market Size and Growth Rate of Crohn’s Disease from 2016 to 2027
-
1.4.4 China LATAM Adalimumab Market Size and Growth Rate of Ulcerative Colitis from 2016 to 2027
-
1.4.5 China LATAM Adalimumab Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of LATAM Adalimumab Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of LATAM Adalimumab by Major Types
-
3.4.1 Market Size and Growth Rate of Oral Type
-
3.4.2 Market Size and Growth Rate of Injection Type
4 Segmentation of LATAM Adalimumab Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of LATAM Adalimumab by Major End-Users
-
4.4.1 Market Size and Growth Rate of LATAM Adalimumab in Rheumatoid Arthritis
-
4.4.2 Market Size and Growth Rate of LATAM Adalimumab in Psoriasis
-
4.4.3 Market Size and Growth Rate of LATAM Adalimumab in Crohn’s Disease
-
4.4.4 Market Size and Growth Rate of LATAM Adalimumab in Ulcerative Colitis
-
4.4.5 Market Size and Growth Rate of LATAM Adalimumab in Others
5 Market Analysis by Regions
-
5.1 China LATAM Adalimumab Production Analysis by Regions
-
5.2 China LATAM Adalimumab Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China LATAM Adalimumab Landscape Analysis
-
6.1 North China LATAM Adalimumab Landscape Analysis by Major Types
-
6.2 North China LATAM Adalimumab Landscape Analysis by Major End-Users
7 Central China LATAM Adalimumab Landscape Analysis
-
7.1 Central China LATAM Adalimumab Landscape Analysis by Major Types
-
7.2 Central China LATAM Adalimumab Landscape Analysis by Major End-Users
8 South China LATAM Adalimumab Landscape Analysis
-
8.1 South China LATAM Adalimumab Landscape Analysis by Major Types
-
8.2 South China LATAM Adalimumab Landscape Analysis by Major End-Users
9 East China LATAM Adalimumab Landscape Analysis
-
9.1 East China LATAM Adalimumab Landscape Analysis by Major Types
-
9.2 East China LATAM Adalimumab Landscape Analysis by Major End-Users
10 Northeast China LATAM Adalimumab Landscape Analysis
-
10.1 Northeast China LATAM Adalimumab Landscape Analysis by Major Types
-
10.2 Northeast China LATAM Adalimumab Landscape Analysis by Major End-Users
11 Southwest China LATAM Adalimumab Landscape Analysis
-
11.1 Southwest China LATAM Adalimumab Landscape Analysis by Major Types
-
11.2 Southwest China LATAM Adalimumab Landscape Analysis by Major End-Users
12 Northwest China LATAM Adalimumab Landscape Analysis
-
12.1 Northwest China LATAM Adalimumab Landscape Analysis by Major Types
-
12.2 Northwest China LATAM Adalimumab Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Novartis AG
-
13.1.1 Novartis AG Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Boehringer Ingelheim GmbH
-
13.2.1 Boehringer Ingelheim GmbH Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Oral Type from 2016 to 2027
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Injection Type from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Rheumatoid Arthritis from 2016 to 2027
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Psoriasis from 2016 to 2027
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Crohn’s Disease from 2016 to 2027
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Ulcerative Colitis from 2016 to 2027
-
Figure China LATAM Adalimumab Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China LATAM Adalimumab Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of LATAM Adalimumab Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of LATAM Adalimumab
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of LATAM Adalimumab by Different Types from 2016 to 2027
-
Table Consumption Share of LATAM Adalimumab by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Oral Type
-
Figure Market Size and Growth Rate of Injection Type
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of LATAM Adalimumab by Different End-Users from 2016 to 2027
-
Table Consumption Share of LATAM Adalimumab by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Rheumatoid Arthritis
-
Figure Market Size and Growth Rate of Psoriasis
-
Figure Market Size and Growth Rate of Crohn’s Disease
-
Figure Market Size and Growth Rate of Ulcerative Colitis
-
Figure Market Size and Growth Rate of Others
-
Table China LATAM Adalimumab Production by Regions
-
Table China LATAM Adalimumab Production Share by Regions
-
Figure China LATAM Adalimumab Production Share by Regions in 2016
-
Figure China LATAM Adalimumab Production Share by Regions in 2021
-
Figure China LATAM Adalimumab Production Share by Regions in 2027
-
Table China LATAM Adalimumab Consumption by Regions
-
Table China LATAM Adalimumab Consumption Share by Regions
-
Figure China LATAM Adalimumab Consumption Share by Regions in 2016
-
Figure China LATAM Adalimumab Consumption Share by Regions in 2021
-
Figure China LATAM Adalimumab Consumption Share by Regions in 2027
-
Table North China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table North China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure North China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure North China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure North China LATAM Adalimumab Consumption Share by Types in 2027
-
Table North China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table North China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure North China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure North China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure North China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table Central China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table Central China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure Central China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure Central China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure Central China LATAM Adalimumab Consumption Share by Types in 2027
-
Table Central China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table Central China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure Central China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure Central China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure Central China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table South China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table South China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure South China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure South China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure South China LATAM Adalimumab Consumption Share by Types in 2027
-
Table South China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table South China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure South China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure South China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure South China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table East China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table East China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure East China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure East China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure East China LATAM Adalimumab Consumption Share by Types in 2027
-
Table East China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table East China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure East China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure East China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure East China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table Northeast China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table Northeast China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure Northeast China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure Northeast China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure Northeast China LATAM Adalimumab Consumption Share by Types in 2027
-
Table Northeast China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table Northeast China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure Northeast China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure Northeast China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table Southwest China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table Southwest China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure Southwest China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure Southwest China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure Southwest China LATAM Adalimumab Consumption Share by Types in 2027
-
Table Southwest China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table Southwest China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure Southwest China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure Southwest China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table Northwest China LATAM Adalimumab Consumption by Types from 2016 to 2027
-
Table Northwest China LATAM Adalimumab Consumption Share by Types from 2016 to 2027
-
Figure Northwest China LATAM Adalimumab Consumption Share by Types in 2016
-
Figure Northwest China LATAM Adalimumab Consumption Share by Types in 2021
-
Figure Northwest China LATAM Adalimumab Consumption Share by Types in 2027
-
Table Northwest China LATAM Adalimumab Consumption by End-Users from 2016 to 2027
-
Table Northwest China LATAM Adalimumab Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China LATAM Adalimumab Consumption Share by End-Users in 2016
-
Figure Northwest China LATAM Adalimumab Consumption Share by End-Users in 2021
-
Figure Northwest China LATAM Adalimumab Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Novartis AG
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG
-
Figure Sales and Growth Rate Analysis of Novartis AG
-
Figure Revenue and Market Share Analysis of Novartis AG
-
Table Product and Service Introduction of Novartis AG
-
Table Company Profile and Development Status of Boehringer Ingelheim GmbH
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim GmbH
-
Figure Sales and Growth Rate Analysis of Boehringer Ingelheim GmbH
-
Figure Revenue and Market Share Analysis of Boehringer Ingelheim GmbH
-
Table Product and Service Introduction of Boehringer Ingelheim GmbH
-
